Results from the ASCEND study, published in New England Journal of Medicine, and the ARRIVE study, published in The Lancet, add to the debate surrounding the efficacy of aspirin in preventing diabetes, heart attacks and/or stroke in at-risk patients.

The benefit of aspirin for preventing second events in patients with a previous heart attack or stroke is well established, but its use to prevent first events is controversial.

Dr. Susan Smyth, director of the Gill Heart and Vascular Institute at the University of Kentucky, is available to comment on the impact of these studies. She has been a part of numerous studies exploring the concept of an aspirin regimen to prevent heart attack and stroke, including:

Broadcast studio available.